Table 5.
Hazard ratio (HRs) and 95 % confidence intervals (CIs) for fractures in the tamoxifen users compared with non-users using the time-dependent model stratified by comorbidity
| Comorbidity | Tamoxifen user vs. non-user HR (95 % CI) | p-value | Interaction p |
|---|---|---|---|
| Hypertension | 0.18 | ||
| No | 0.67 (0.53-0.85) | 0.001 | |
| Yes | 0.55 (0.46-0.66) | <0.0001 | |
| Hyperlipidemia | 0.97 | ||
| No | 0.60 (0.50-0.72) | <0.0001 | |
| Yes | 0.58 (0.45-0.74) | <0.0001 | |
| Diabetes | 0.56 | ||
| No | 0.62 (0.52-0.74) | <0.0001 | |
| Yes | 0.54 (0.41-0.71) | <0.0001 | |
| PAD | 0.58 | ||
| No | 0.59 (0.50-0.68) | <0.0001 | |
| Yes | 0.73 (0.37-1.46) | 0.38 | |
| Stroke | 0.32 | ||
| No | 0.59 (0.50-0.69) | <0.0001 | |
| Yes | 0.68 (0.41-1.13) | 0.14 | |
| Osteoporosis | 0.33 | ||
| No | 0.61 (0.51-0.73) | <0.0001 | |
| Yes | 0.54 (0.40-0.72) | <0.0001 |
PAD, peripheral artery disease
Manually adjusted for monthly income, comorbidity and aromatase inhibitor use before the end point